Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia

The standard-of-care treatment of T-cell acute lymphoblastic leukaemia (T-ALL) with chemotherapy usually achieves reasonable rates of initial complete response. However, patients who relapse or do not respond to conventional therapy show dismal outcomes, with cure rates below 10% and limited therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa-Morales, María, Pérez-Gómez, Laura, Pérez-Gómez, Eduardo, López-Nieva, Pilar, Fernández-Navarro, Pablo, Santos, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299336/
https://www.ncbi.nlm.nih.gov/pubmed/37373496
http://dx.doi.org/10.3390/ijms241210350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299336/
https://www.ncbi.nlm.nih.gov/pubmed/37373496
http://dx.doi.org/10.3390/ijms241210350

Ejemplares similares